Bide Pharmatech Co

Bide Pharmatech Co Intangible Assets

The Intangible Assets of Bide Pharmatech Co (688073.SS) as of Nov 3, 2026 is 3.95 M CNY. In the previous year, Intangible Assets was 600,000.00 CNY — a change of 558.33% (higher).

Intangible Assets

3.95 MCNY

YoY

558.33%

Last updated:

Intangible Assets of Bide Pharmatech Co is 2024 3.95 M CNY. Intangible Assets of Bide Pharmatech Co was 2023 600,000.00 CNY. It decreases by 558.33% higher compared to the previous year.

The Bide Pharmatech Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2020
675,800.00 CNY
Jan 1, 2021
442,800.00 CNY
Jan 1, 2022
211,800.00 CNY
Jan 1, 2023
600,000.00 CNY
Jan 1, 2024
3.95 M CNY
The Bide Pharmatech Co Intangible Assets history
YEARIntangible AssetsYoY
3.95 MCNY+558.33%
600,000.00CNY+183.29%
211,800.00CNY-52.17%
442,800.00CNY-34.48%
675,800.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bide Pharmatech Co Stock analysis

What does Bide Pharmatech Co do? Bide Pharmatech Co., Ltd. generates revenue through the research, development, design, production, and sales of pharmaceutical molecular building blocks and scientific reagents. The company's primary products serve drug target discovery, seed compound screening, lead compound discovery, synthesis, and optimization processes. Key markets include Asia Pacific, India, Europe, and the United States, where the firm's offerings are utilized by pharmaceutical companies and research institutions. The business model relies on direct sales of its specialized chemical products to these industry segments. The firm's main focus is on developing molecular building blocks for drug development, with products specifically designed for early-stage pharmaceutical research. These building blocks are essential for creating and refining potential drug candidates. The company's operations span multiple global regions, targeting pharmaceutical manufacturers and academic research organizations that require high-quality chemical compounds for their development pipelines. Bide Pharmatech's revenue streams are derived from the sale of its proprietary molecular building blocks and reagents, which are integral to pharmaceutical R&D processes. The company serves clients in the pharmaceutical sector across Asia Pacific, India, Europe, and the United States, delivering products that support critical stages of drug discovery and development. Bide Pharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bide Pharmatech Co stock

Intangible Assets of Bide Pharmatech Co is 3.95 M CNY in 2024.

Intangible Assets of Bide Pharmatech Co changed from 600,000.00 CNY to 3.95 M CNY, representing a 558.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Bide Pharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Bide Pharmatech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bide Pharmatech Co

All Key Metrics — Bide Pharmatech Co